Table 1. Patients' characteristics.
|
PB
|
BM
|
||||||
|---|---|---|---|---|---|---|---|
| CK-19+ | CK-19− | P-value | CK-19+ | CK-19− | P-value | ||
| Patients enrolled (n) | 165 | 91 | 74 | 95 | 70 | ||
| Age (years) | |||||||
| Median | 54 | 54 | 54.5 | 0.647 | 54 | 53 | 0.877 |
| Range | 26–75 | 26–74 | 36–75 | 26–74 | 36–75 | ||
| n (%) |
n (%) |
n (%) |
|||||
| Menopausal status | |||||||
| Pre-menopausal | 78 (47.3) | 45 (49.5) | 33 (44.6) | 0.534 | 44 (46.3) | 34 (48.6) | 0.774 |
| Post-menopausal | 87 (52.7) | 46 (50.5) | 41 (55.4) | 51 (53.7) | 36 (51.4) | ||
| Tumour size (cm) | |||||||
| <2.0 | 54 (32.7) | 27 (29.7) | 27 (36.5) | 0.650 | 29 (30.5) | 25 (35.7) | 0.768 |
| 2.0–5.0 | 97 (58.8) | 56 (61.5) | 41 (55.4) | 58 (61.1) | 39 (55.7) | ||
| >5.0 | 14 (8.5) | 8 (8.8) | 6 (8.1) | 8 (8.4) | 6 (8.6) | ||
| Lymph nodes | |||||||
| 0 | 59 (35.8) | 28 (30.8) | 31 (41.9) | 0.240 | 30 (31.6) | 29 (41.4) | 0.294 |
| 1–3 | 59 (35.8) | 33 (36.3) | 26 (35.1) | 34 (35.8) | 25 (35.7) | ||
| ⩾4 | 47 (28.5) | 30 (33.0) | 17 (23.0) | 31 (32.6) | 16 (22.9) | ||
| Histology grade | |||||||
| I/II | 79 (47.9) | 41 (45.1) | 38 (51.4) | 0.669 | 44 (46.3) | 35 (50.0) | 0.800 |
| III | 64 (38.8) | 38 (41.8) | 26 (35.1) | 37 (38.9) | 27 (38.6) | ||
| Lobulara | 22 (13.3) | 12 (13.2) | 10 (13.5) | 14 (14.7) | 8 (11.4) | ||
| ER status | |||||||
| ER+ | 101 (61.2) | 59 (64.8) | 42 (56.8) | 0.290 | 60 (63.2) | 41 (58.6) | 0.550 |
| ER− | 64 (38.8) | 32 (35.2) | 32 (43.2) | 35 (36.8) | 29 (41.4) | ||
| PR status | |||||||
| PR+ | 88 (53.3) | 50 (54.9) | 38 (51.4) | 0.645 | 50 (52.6) | 38 (54.3) | 0.833 |
| PR− | 77 (46.7) | 41 (45.1) | 36 (48.6) | 45 (47.4) | 32 (45.7) | ||
| HER2 status (ICH) | |||||||
| Negative (0–2) | 131 (79.4) | 78 (85.7) | 58 (78.4) | 0.290 | 82 (86.3) | 54 (77.1) | 0.176 |
| Positive (3+) | 33 (20.0) | 13 (14.3) | 15 (20.3) | 13 (13.7) | 15 (21.4) | ||
| UN | 1 (0.6) | 1 (1.3) | 1 (1.4) | ||||
| Surgery | |||||||
| S | 119 (72.1) | 62 (68.1) | 57 (77.0) | 0.205 | 64 (67.4) | 55 (78.6) | 0.113 |
| T | 46 (27.9) | 29 (31.9) | 17 (23.0) | 31 (32.6) | 15 (21.4) | ||
| Adjuvant chemotherapy | |||||||
| FEC | 60 (36.4) | 37 (40.7) | 23 (31.1) | 0.055 | 37 (38.9) | 23 (32.9) | 0.055 |
| T/EC | 98 (59.4) | 53 (58.2) | 45 (60.8) | 57 (60.0) | 41 (58.6) | ||
| CMF | 7 (4.2) | 1 (1.1) | 6 (8.1) | 1 (1.1) | 6 (8.6) | ||
| RT | |||||||
| Yes | 144 (87.3) | 83 (91.2) | 61 (82.4) | 0.093 | 85 (89.5) | 59 (84.3) | 0.323 |
| No | 21 (12.7) | 8 (8.8) | 13 (17.6) | 10 (10.5) | 11 (15.7) | ||
BM=bone marrow; CK-19=cytokeratin-19; ER=oestrogen receptor; PR=progesterone receptor; PB=peripheral blood; RT=radiotherapy; S=segmentectomy/lumpectomy; T=total radical mastectomy; UN=unknown.
a
Lobular carcinomas (n=22) are not scored by histological grade.